Category: Events

The Biomedical Research Institute A Coruña (INIBIC) organizes the V Edition of Biomedical Cancer Research Conference in Galicia (IBCG-2018). On October 4th, Ceres Fernández, will be sharig an oral communication on PanCanRisk’s results.

This conference will bring together basic and clinical experts who are working on the most innovative current research topics in human malignancies and animal models, including inmunooncolgy, metastasis-associated microbiota, tumor heterogeneity, cancer and inflammation and novel therapies. The purpose of this conference is to provide a stimulating and interactive environment, including a session to promote the participation of researchers at early stages of their training.

  • The European project PanCanRisk, with participation from the EBI-EMBL and Protein Logic, investigates new mechanisms of hereditary transmission of cancer in order to improve prevention and diagnosis
  • The European consortium, led by Ángel Carracedo’s team at the Galician Public Foundation of Genomic Medicine, will meet this week in Santiago de Compostela to evaluate the project’s achievements

In 2014, an ambitious European genetic research project started with the main objective of identifying new hereditary cancer risk factors. Led from Santiago de Compostela by the team of Dr. Ángel Carracedo at the Galician Public Foundation of Genomic Medicine, PanCanRisk –Personalised Bioinformatics For Global Cancer Susceptibility Identification & Clinical Management– involves over 20 researchers from six institutes and reference research centers across Europe, two of which are based here in Cambridge.

The project is based on the fact that current technologies allow us to obtain and analyze large amounts of genetic data quickly and relatively easily. Noting the need for an adapted statistical analysis, they propose to improve the current algorithms by developing new methods. The goal: to find new genes related to the risk of developing cancer among the tide of currently available data.

The solidity of the approach and the excellence of the research teams involved warranted funding for 2.9M € from the European Union H2020 program for a three-year project.

In addition to the large-scale statistical analysis, the project also considers the validation of the results in real samples of patients obtained from usual clinical processes, such as colon and breast screening programs. Subsequently, functional models that can be applied to clinical practice will be designed, aimed to improve detection, prevention and diagnostic protocols.

Today, the PanCanRisk team faces the final stretch of the project. On June 18th an 19th, an international meeting will be held in Santiago de Compostela to share the progress and results obtained. We will know then if PanCanRisk can deliver on their promise to deliver an earlier diagnosis and more tailored risk screening strategies.

Where: Santiago de Compostela (España)     When: 18/09/2017 – 20/09/2017

Institut Curie, Paris (France) 5-6 October 2017

Results of cross consortium analyses and overlapping results with other consortia were showed in this meeting, and the focus of each discussion was about on data collected, data analysis and timing of deliverables and milestones. Also, the partners initiated the coordination for the second phase of the project, much more functional.

 

Video 1: Welcome – click here

Video 2: Vincenzo L. Pascali “Ethical and legal aspects of giant database storage”– click here

Video 3. Ana Marzo “Legal horizons in the treatment of genomic data” – click here

Video 4. Ferrán Sanz “Data protection in the cloud” – click here

Video 5. Carlos Romeo “Health Big Data and the Cloud: a new challenge for law” – click here

Video 6. Discussion – click here

Continue Reading

Centre for Genomic Regulation (CGR), Barcelona (Spain) 13-14 December 2016

The partners analyzed the progress of the project, with its advances and needs. Stephan Ossowski explained the development of IT tools to analyse large data sets of cancer, whole genome and whole exome data. Until then, there were about 3400 genomes of cancer patients and 15.000 whole exomes.

In the PCAWG compared about 22 different cancers, but each one of them comes from a specific country that has provided the data for it. Also, In FPGMX had a study scheduled an approach of 200 genes and select the best ones for a validation study.

Also, on December 14th, took place in Barcelona the mini-symposium “Private health data in the cloud”. This event, organized by the PanCanRisk consortium is aimed mainly at research groups and organizations, Students, Project Managers Patients and Legal Advisers interested in the protection of health data, especially genetic data.

Ethics Advisory Board (EAB) of the Consortium PanCanRisk

The EAB of the consortium PanCanRisk had a meeting on the 14Th December 2016, at the Centre for Genomic Regulation (CRG), with the aim of performing an Ethical Screening of the activities of the consortium PanCanRisk and to assess any new ethical issues that might arise during the development of the activities of the consortium.

The members of Ethics Advisory Board (EAB) of the Consortium PanCanRisk are composed by 3 independent and external members with relevant experience in ethics:

– Helena Machado, Research Professor at Centre for Social Studies, University of Coimbra, Portugal

– Carlos Romeu, Tenured Professor of Criminal Law at Univrsity of the Basque Country, Spain

– Vincenzo Lorenzo Pascali, Professor at Facoltà di Medicina e Chirurgia, Sede di  Roma. Istituto di sanita’ pubblica, Italy

simposio

Next Wednesday, December 14th, will take place in Barcelona the mini-symposium “Private health data in the cloud”.

This event, organized by the PanCanRisk consortium (pancanrisk.eu) is aimed mainly at research groups and organizations, Students, Project Managers Patients and Legal Advisers interested in the protection of health data, especially genetic data.

The objective is to analyze the novelties of the new European Law of data protection and to comment with experts in the matter ethical and legal issues and the need to conciliate data security with the anonymity that is needed to preserve the identity of subjects that are tested at the clinical trials and research projects.

While data is being produced, analyzed and reanalysed at a very high speed, we lack a common ethical and legal framework to facilitate genomic and clinical data, global science collaboration, and responsible research conduct. An international code of conduct should be designed to enable global genomic and clinical data sharing for biomedical research within a human rights framework has been proposed.

In the following link you can find the program.

Registration is free, but please confirm your assistance by mail (info@pancanrisk.eu) in order to access to the PRBB building.

We look forward to your participation and welcome your feedback via Twitter at @pancanrisk and with the HT #PrivateHealthData

 

Wellcome Genome Campus Conference Centre, Hinxton, Cambridge (UK), 30-31 May 2016

The partners analyzed the progress of PanCanRisk project during the first year and also, they defined specific goals and next steps. Firstly, Stephan Ossowski discussed the development of a computational platform for sequencing-based cancer risk analysis, and Ángel Carracedo mentions that the compilation of the germline variants are very important, regardless of whether they have controls to compare patients suffering from cancer to people without the disease, and proposes the addition of other exomes from people affected by many different diseases, but mainly cancer. Stephan Ossowski reiterates that at least 100 exomes have to be added to the database each time to avoid tracing the information back to person.

Then, Hana Susak discussed tools for rare and common variant association analyses in cancer studies, Oliver Stegle analysed the identification of regulatory variants and eQTLs, integrating germline and somatic mutations and phenotypes. Gabriella Palacios and Ceres Fernandez also discussed her side of replication and clinical validation in cancer and cancer-risk cohorts.

Finally, Roslin Russell discussed the computational biomarker development for cancer predisposition genes and Aura Carreira the functional study of identified risk genes and regulatory variants.

 

AC Hotel Palacio del Carmen. Santiago de Compostela (Galicia-Spain)  8th-9th July 2015

The PanCanRisk project aims to apply bioinformatics for global identification of genetic susceptibility to cancer and clinical management. It is coordinated by the team of Professor Ángel Carracedo in the Fundación Pública Galega de Medicina Xenómica(FPGMX), and is part of the European Commission Program Horizon 2020. Our first meeting took place in Santiago de Compostela, in July 2015, with the aim of promoting the Pancanrisk project. In the first session, introduced by Ángel Carracedo, all the partners introduced ourselves and we knew our structure and organization.

Then, in the Scientific Work Packages, the partners analyzed their role in the project. Stephan Ossowski analyzed the development of a computational platform for sequencing-based cancer risk analysis and Xavier Stivill talked about the tools for rare and common variant association analyses in cancer studies. Next, Oliver Stegle explained the identification process of regulatory variants and eQTLS, integrating germline and somatic mutations and phenotypes.

Replication and clinical validation in cancer, with Anna Abulí, functional study of identified risk genes and regulatory variants, with Aura Carreira, and computational biomarker development for cancer predisposition genes with Mahesh Shah were also discussed.

On the second day, Domenico Lalli, legal officer at DG Research & Innovation European Commission, analyzed the practical aspects of Horizon 2020 projects and advices for PanCanRisk. Also, the ethical and legal issues were explained by Ángel Carracedo, who guided the project’s partners to a visit to Fundación Pública Galega de Medicina Xenómina and Innopharma.